Drug intelligence / Profile preview

MEB-1997

Development stage: Preclinical
Lead developer: Mebias Discovery
Modality: Small Molecules

Overview

MEB-1997 is a small molecule drug candidate developed by Mebias Discovery. It acts as a modulator of the sphingosine 1-phosphate receptor subtype 1 (S1PR1), also known as Edg-1. The primary therapeutic area under investigation is nervous system diseases, with neuralgia identified as an active indication. As of the latest updates, MEB-1997 remains in preclinical development and has not yet advanced to clinical trials or received regulatory approval[1][2].

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on MEB-1997.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEB-1997.

Explore the full profile